Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma Without HLH and Low Tumor Burden
This protocol covers first-line management of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) in patients who present without hemophagocytic lymphohistiocytosis (HLH) and whose disease is localized or limited in extent.
Clinical Scenario
SPTCL without hemophagocytic lymphohistiocytosis (HLH) and with low tumor burden — localized or limited subcutaneous disease. In the absence of HLH, immunomodulatory approaches are favored over chemotherapy as the basis of first-line treatment.
Treatment Approach — partial overview
First-line options include immunomodulatory single-agent therapy, with or without corticosteroids, or local approaches for limited disease. The specific agents, their sequencing, and all dose guidance are detailed in the full protocol.
Treatment Goals
The primary endpoint of first-line therapy is achieving a complete response (CR) or partial response (PR).
References
- SPTCL Without HLH and Low Tumor Burden (Localized or Limited Subcutaneous Disease)
- While chemotherapy may be considered for patients presenting with HLH, immunomodulatory therapies are considered for patients who present without HLH.
- Single agents (CsA, methotrexate, or bexarotene), with or without prednisone, can be considered as options for first-line therapy.
- ISRT can be considered as a local therapy for single lesion or limited disease with and without symptoms of HLH.
- Depending on the response to first-line therapy (CR or PR), options such as observation or single-agent maintenance therapy are recommended.
View source ↗